Novartis’ Femara improves long-term breast cancer survival
The trial was designed to determine whether longer-term treatment with an aromatase inhibitor (Femara) post tamoxifen therapy, would offer any clinical benefit to postmenopausal women with early breast
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.